Trials / Completed
CompletedNCT02164006
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TGR-1202 + brentuximab vedotin | TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin |
Timeline
- Start date
- 2014-06-11
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2014-06-16
- Last updated
- 2019-10-02
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02164006. Inclusion in this directory is not an endorsement.